Immunome, Inc.
IMNM Healthcare Biotechnology
Immunome, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $6.9 million, down 23.2% from fiscal 2024.
- Revenue
- +69.8%
- EPS
- −30.0%
- Free cash flow
- −27.0%
Quarter to June 2026, against a year earlier
Follow IMNM
Alert me
Immunome, Inc. (IMNM) EV/FCF
As of 5 November 2026, Immunome, Inc. (IMNM) trades at a EV/FCF of −7.0×. Over the past ten years it has ranged from −48.2× (March 2024) to 33.0× (June 2023); the current reading is higher than 35% of that period.
EV/FCF, daily
Embed this chart
Annual newest first
| Period | EV/FCF | Change |
|---|---|---|
| FY2025 | −6.1× | — |
| FY2024 | −3.4× | — |
| FY2023 | −9.6× | — |
Quarterly newest first
| Period | EV/FCF | Change |
|---|---|---|
| Jun 2025 | −2.9× | — |
| Mar 2025 | −1.3× | — |
| Dec 2024 | −3.4× | — |
| Sep 2024 | −6.9× | — |
| 6 more quarters | Free account |
Against its own ten years
EV/FCF against peers
| Company | EV/FCF |
|---|---|
| PVLA Palvella Therapeutics, Inc. compare | −62.4× |
| IMNM Immunome, Inc. | −7.0× |
| CLDX Celldex Therapeutics, Inc. compare | −6.2× |
| VERA Vera Therapeutics, Inc. compare | −5.2× |
| BHVN Biohaven Ltd. compare | −4.5× |
| LKFT Lakefront Biotherapeutics - Sponsored ADR compare | 0.6× |
| AUPH Aurinia Pharmaceuticals Inc compare | 9.7× |
| ADMA ADMA Biologics Inc compare | 25.2× |
| VCEL Vericel Corporation compare | 42.8× |
What EV/FCF is
EV/Free CF shows how the value of a whole company, debt included, compares with the free cash its business produces.
((Stock Price × Shares (Basic, Weighted) (latest quarter)) + (Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter)) − Cash & Short Term Investments (latest quarter)) ÷ (Operating Cash Flow (TTM) + Property, Plant, Equipment Change (Net) (TTM) + Intangible Assets Change (Net) (TTM))
More on IMNM
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Altman Z-score
- The full statement